Cosmos Health CEO Greg Siokas Adds 3,398,055 Shares Year-to-Date 2025 Following Continued November Purchases
MWN-AI** Summary
On December 2, 2025, Cosmos Health Inc. (NASDAQ:COSM) announced that Chief Executive Officer Greg Siokas has significantly increased his stake in the company, acquiring an additional 301,101 shares in November alone. Year-to-date, his total acquisitions for 2025 have reached 3,398,055 shares, elevating his overall ownership to 6,459,985 shares. Siokas attributes this expansion to the company's record-breaking performance in Q3 2025, which showcased unprecedented growth in revenue, gross profits, and margins across its core business sectors. He emphasized his belief that Cosmos is positioned to create substantial value moving forward, despite facing valuation pressures.
Cosmos Health is a diverse global healthcare group engaged in pharmaceuticals and nutraceuticals with brands including Sky Premium Life® and Mediterranation®. The company operates under GMP standards in Europe through its subsidiary Cana Laboratories S.A. It manufactures a wide range of health products and distributes them through subsidiaries in Greece and the UK. Additionally, Cosmos is innovating in the research and development of novel products targeting serious health issues such as obesity and diabetes, further enhanced by its use of artificial intelligence for drug repurposing.
Siokas remains committed to supporting the company as it continues its expansion strategy across Europe, Asia, and North America, recently enhancing its portfolio by acquiring ZipDoctor, Inc. for telehealth services. As Cosmos Health pursues its objectives, stakeholders are encouraged to monitor the company's filings with the SEC and stay informed about potential risks and future developments.
MWN-AI** Analysis
In recent developments, Cosmos Health Inc. (NASDAQ: COSM) has exhibited significant insider buying, highlighted by CEO Greg Siokas’ acquisition of over 3.3 million shares in 2025. This pattern underscores a critical level of confidence in the company's future potential, particularly following the reporting of record Q3 results. The notable increase in Siokas’ holdings, now totaling nearly 6.5 million shares, suggests a strong belief in the company's strategic direction amidst current market pressures.
Despite achieving record quarterly revenues and gross margins, Cosmos Health's stock performance has not reflected these successes adequately. This dichotomy may indicate an undervalued stock, making it an attractive opportunity for investors seeking value plays in the healthcare sector. The company’s ongoing revenue growth driven by diverse business segments—ranging from pharmaceuticals to nutritional products—coupled with strategic international expansions, points to robust fundamentals that investors should consider.
Moreover, the CEO’s clear commitment to support the company through increased personal investment indicates strong leadership alignment with shareholder interests. This sentiment is further strengthened by the company's focus on R&D partnerships and its strategic entry into telehealth through ZipDoctor, offering a comprehensive approach in a rapidly evolving healthcare landscape.
However, potential investors should maintain a cautious outlook given existing market apprehensions, including geopolitical risks and the company’s broader ability to sustain its growth trajectory. To capitalize on the potential upside of Cosmos Health, investors might consider accumulating shares during periods of volatility, especially as the company expands its pipeline of innovative products and explores global markets.
In conclusion, current market dynamics coupled with CEO insider buying present a compelling case for potential investment in Cosmos Health, while careful monitoring of external risks remains essential.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
CHICAGO, Dec. 02, 2025 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the “Company”) (NASDAQ:COSM) , a diversified, vertically integrated global healthcare group, today announced that Chief Executive Officer Greg Siokas has further increased his ownership in the Company through continued share acquisitions during November 2025.
Specifically, between 19 November and 28 November 2025, Mr. Siokas executed five transactions, acquiring 301,101 shares.
So far in 2025, he has added 3,398,055 shares to his holdings.
Following these acquisitions, his total ownership has increased to 6,459,985 shares of Cosmos Health.
Greg Siokas, CEO of Cosmos Health, stated: “We recently reported record-breaking Q3 2025 results, and I expect this strong momentum to continue into Q4. Despite our all-time-high achievements in quarterly revenue, gross profit and gross margins, driven by robust growth across all core business segments, our valuation remains under pressure.
I have increased my ownership by well over three million shares since the beginning of the year because I firmly believe Cosmos is well positioned to deliver significant value. I remain committed to supporting the Company in every way necessary so that we can achieve our objectives as we expand globally and advance our pipeline of innovative products.”
Information on Mr. Siokas’s Recent Transactions:
Please refer to the filings on Form 4 filed with the SEC and available on the SEC's website for more information about the nature of the transactions, including details such as “Ownership Form”, “Transaction Date”, “Amount”, “Price”, and other relevant information regarding the shares acquired by Mr. Siokas.
About Cosmos Health Inc.
Cosmos Health Inc. (Nasdaq:COSM), incorporated in 2009 in Nevada, is a diversified, vertically integrated global healthcare group. The Company owns a portfolio of proprietary pharmaceutical and nutraceutical brands, including Sky Premium Life®, Mediterranation®, bio-bebe®, C-Sept® and C-Scrub®. Through its subsidiary Cana Laboratories S.A., licensed under European Good Manufacturing Practices (GMP) and certified by the European Medicines Agency (EMA), it manufactures pharmaceuticals, food supplements, cosmetics, biocides, and medical devices within the European Union. Cosmos Health also distributes a broad line of pharmaceuticals and parapharmaceuticals, including branded generics and OTC medications, to retail pharmacies and wholesale distributors through its subsidiaries in Greece and the UK. Furthermore, the Company has established R&D partnerships targeting major health disorders such as obesity, diabetes, and cancer, enhanced by artificial intelligence drug repurposing technologies, and focuses on the R&D of novel patented nutraceuticals, specialized root extracts, proprietary complex generics, and innovative OTC products. Cosmos Health has also entered the telehealth space through the acquisition of ZipDoctor, Inc., based in Texas, USA. With a global distribution platform, the Company is currently expanding throughout Europe, Asia, and North America, and has offices and distribution centers in Thessaloniki and Athens, Greece, and in Harlow, UK. More information is available at www.cosmoshealthinc.com , www.skypremiumlife.com , www.cana.gr , www.zipdoctor.co , www.cloudscreen.gr , as well as LinkedIn and X .
Forward-Looking Statements
With the exception of the historical information contained in this news release, the matters described herein may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Words such as “believes,” “expects,” “anticipates,” “intends,” “projects,” “estimates,” “plans,” and similar expressions, or future or conditional verbs such as “will,” “should,” “would,” “may,” and “could,” generally identify forward-looking statements, although not all forward-looking statements contain these words. These statements involve risks and uncertainties that may individually or materially affect the matters discussed herein for a variety of reasons outside the Company’s control, including, but not limited to: the Company’s ability to raise sufficient financing to implement its business plan; the effectiveness of its digital asset strategies, including accumulation and yield-generating activities; the impact of the war in Ukraine on the Company’s business, operations, and the economy in general; and the Company’s ability to successfully develop and commercialize its proprietary products and technologies. Readers are cautioned not to place undue reliance on these forward-looking statements, as actual results could differ materially from those anticipated. Readers are encouraged to review the risk factors set forth in the Company’s filings with the SEC, which are available at the SEC’s website ( www.sec.gov ). The Company disclaims any obligation to update or revise forward-looking statements, whether as a result of any new information, future events, or otherwise.
Investor Relations Contact:
BDG Communications
cosm@bdgcommunications.com
Disclaimer
This electronic content is for the purposes of solicitation subscriptions for Market Wire News. Market Wire News expects to generate new advertisement revenue resulting from the distribution of this electronic content. The amount of which is unknown at this time. Market Wire News is not a registered investment adviser or broker-dealer. This electronic content does not provide a professional analysis of a COSM financial position. COSM financial position and all other information regarding the featured Company should be verified directly with COSM. This electronic content is provided as an information service only, and any statements and opinions in this electronic content should not be construed as an offer or solicitation to buy or sell any security. Market Wire News accepts no liability for any loss arising from an investor's reliance on or use of this electronic content. An investment in COSM is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. Market Wire News does not own, buy, sell or plans to own, buy, sell, and of COSM shares. This electronic content contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Compensation: Market Wire News and its affiliates has received six thousand dollars for Market Wire News advertising services from Relqo Media LLC for Brand Awareness Distribution, Corporate Communications, News, Press Release Enhancement and Social Media Solutions starting 2026-05-31 and ending 2026-06-05 provided by Market Wire News. To date, we have received a total of six thousand dollars. Please read our full disclaimer for compensation and more detailed information.
FAQ**
How does Greg Siokas’s recent acquisition of 301,101 shares impact investor confidence in Cosmos Holdings Inc. (COSM) as the company continues to achieve record-breaking financial results?
What specific strategies does Cosmos Holdings Inc. (COSM) plan to employ in order to address the current pressure on its valuation despite strong quarterly performance?
Can you elaborate on the innovative products Cosmos Holdings Inc. (COSM) is developing through its R&D partnerships aimed at addressing significant health disorders?
Given the geopolitics affecting the market, how is Cosmos Holdings Inc. (COSM) preparing to mitigate potential risks, such as those posed by the war in Ukraine, to ensure business continuity?
**MWN-AI FAQ is based on asking OpenAI questions about Cosmos Health Inc. (NASDAQ: COSM).
NASDAQ: COSM
COSM Trading
-3.36% G/L:
$0.2505 Last:
367,675 Volume:
$0.264 Open:
